Physician profile
Robert Graham
NPI 1720117138
$3,677.33
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $1,173 · 2021: $882 · 2022: $587 · 2023: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $159.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $934.27 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $662.36 | 2019-2022 | |
| Merz North America, INC. | $344.30 | 2019 | |
| Allergan, INC. | $310.95 | 2019-2022 | |
| Lilly USA, LLC | $263.42 | 2019-2023 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.01 | 2020-2022 | |
| Pfizer INC. | $203.50 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $137.68 | 2021 | |
| Eisai INC. | $87.67 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.64 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $58.49 | 2019-2020 | |
| Horizon Therapeutics Plc | $58.25 | 2021 | |
| Novo Nordisk INC | $39.67 | 2019-2023 | Wegovy |
| Axsome Therapeutics, INC. | $31.72 | 2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.24 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $23.32 | 2022 | |
| Merck Sharp & Dohme LLC | $21.94 | 2020 | |
| Exact Sciences Corporation | $21.45 | 2023 | Cologuard Collection Kit |
| Zyla Life Sciences, INC. | $20.83 | 2020 | |
| Assertio Therapeutics, INC. | $19.33 | 2020 | |
| Gilead Sciences, INC. | $18.80 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.54 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.60 | 2022 | |
| Abbott Laboratories | $16.15 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.